Solid Tumor Cancers
BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. This would be a first-in-class drug with these dual properties. Preclinical and clinical programs are currently focused on Lung, Prostate and Head and Neck Cancers. Humanetics is receiving funding from the National Cancer Institutes for these programs. Learn more.
The U.S. Government and Military have prioritized the need for medical countermeasures for accidental or intentional radiological events. BIO 300 has received extensive funding from the Department of Defense and the Biomedical Research and Development Authority (BARDA). Learn more.
There is also significant interest in BIO 300 from NASA to protect astronauts from space radiation events during space flight. Humanetics has received grant funding from the National Space Biomedical Research Institute and direct from NASA to test BIO 300 against space-like radiation.